CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Mapping the frontiers: a bibliometric perspective on t cell-based immunotherapy in pancreatic cancer since the twenty-first century.
Mapping the frontiers: a bibliometric perspective on t cell-based immunotherapy in pancreatic cancer since the twenty-first century.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T 细胞免疫治疗用于 PC 是一个快速发展的跨学科领域，由美国引领，中国的贡献日益增加。加速临床转化需要：将 T 细胞工程与微环境重塑相结合；与检查点和基质靶向药物进行合理联合；建立稳健的预测性生物标志物及标准化终点；安全工程和风险缓解框架；以及协调的多中心合作。本文献计量学综述描绘了该领域的结构和优先事项，以改善 PC 患者的预后。
T细胞免疫治疗正在重塑癌症治疗格局，并为胰腺癌（PC）提供了一种靶向策略，但目前尚缺乏对其研究轨迹的全面描绘。我们旨在勾勒该领域的演变历程，识别主要贡献者，并阐明正在塑造临床转化的主题转变。
我们系统分析了2000年1月至2024年12月期间收录于Web of Science核心合集Science Citation Index Expanded的文章和综述。汇总文献元数据，用于描述性趋势分析以及合著、共被引和关键词共现网络的科学映射。采用时间趋势分析以突出新兴主题。
过去二十年，全球关于PC的T细胞免疫治疗产出显著扩大，但各地区分布仍不均衡。美国在学术影响力和转化影响力方面领先，中国在发文量和高影响力机构贡献方面紧随其后。研究已汇聚于免疫治疗、肿瘤微环境调控和细胞工程的交叉领域。主导主题包括工程化T细胞方法、免疫检查点调控以及利用TIL（肿瘤浸润淋巴细胞）的策略。新兴前沿涵盖AI赋能的靶点/药物发现、生物标志物指导的患者分层和个体化治疗设计。持续存在的障碍包括在促结缔组织增生和免疫抑制性PC微环境中疗效有限、原发性和获得性免疫抵抗、安全性问题以及监管和试验设计的复杂性。
T-cell immunotherapy is reshaping cancer care and offers a targeted strategy for pancreatic carcinoma (PC), yet a comprehensive map of its research trajectory is lacking. We aimed to chart the evolution of the field, identify leading contributors, and clarify the thematic shifts that are shaping clinical translation.
We systematically analyzed articles and reviews indexed in the Science Citation Index Expanded of the Web of Science Core Collection from January 2000 to December 2024. Bibliographic metadata were aggregated for descriptive trend analyses and science-mapping of co-authorship, co-citation, and keyword co-occurrence networks. Temporal trend profiling was used to highlight emerging topics.
Global output on T-cell immunotherapy for PC has expanded markedly over the past two decades but remains unevenly distributed across regions. The United States leads in academic influence and translational impact, with China closely following in publication volume and contributions from high-impact institutions. Research has converged at the interface of immunotherapy, tumor-microenvironment modulation, and cellular engineering. Dominant themes include engineered T-cell approaches, immune-checkpoint modulation, and strategies leveraging tumor-infiltrating lymphocytes. Emerging fronts encompass AI-enabled target/drug discovery, biomarker-guided patient stratification, and individualized treatment designs. Persisting barriers include limited efficacy in the desmoplastic and immunosuppressive PC microenvironment, primary and acquired immune resistance, safety concerns, and regulatory and trial-design complexities.
T-cell immunotherapy for PC is a rapidly advancing, interdisciplinary domain led by the United States with rising contributions from China. Accelerating clinical translation will require: integrated T-cell engineering with microenvironment remodeling; rational combinations with checkpoint and stroma-targeted agents; robust predictive biomarkers with standardized endpoints; safety-engineering and risk-mitigation frameworks; and coordinated, multicenter collaboration. This bibliometric synthesis delineates the field's structure and priorities to improve outcomes for patients with PC.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
